Medical aesthetics company that produced injectable implant products used in minimally invasive soft tissue augmentation procedures
BioForm Medical was a medical aesthetics company focused on developing and commercializing products used by physicians to enhance a patient’s appearance. The company was a leader in the dermal filler market in the United States and Europe with its flagship product, RADIESSE®, for which it obtained FDA approval for the correction of moderate to severe folds and wrinkles in 2005. The company’s pipeline also included a number of additional aesthetics products, including a radiofrequency treatment to reduce nerve function in the forehead, a sclerotherapy treatment for spider veins, and a surgical adhesive for brow lifts. The company completed its initial public offering in 2007.
- Essex Woodlands invested in BioForm in 2004, having identified the medical aesthetics space as an interesting, high growth area with no reimbursement risk.
- In January 2010, Merz Pharma Group, a privately-held company based in Germany, announced the acquisition of BioForm Medical for $5.45 per share in cash, for a total equity value of approximately $253 million.